Jan 12 (Reuters) – AbbVie said on Monday it would partner with RemeGen to develop an experimental treatment for solid tumors in a deal worth up to $4.95 billion, including milestones.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
Comments